港股异动 | 信达生物(01801)涨超5% IBI363（PD-1/IL-2α-bias）等多款管线将亮相2025 ASCO

智通财经2025-04-24

智通财经APP获悉，信达生物(01801)涨超5%，截至发稿，涨5.05%，报54.05港元，成交额15.91亿港元。消息面上，4月24日，信达生物宣布将在美国临床肿瘤学会（ASCO）年会上展示肿瘤创新管线的一系列临床数据。其中，IBI363（PD-1/IL-2α-bias）在黑色素瘤、肠癌、非小细胞肺癌的临床研究，以及 IBI343（CLDN18.2 ADC）在胰腺癌研究方面均有口头报告。信迪利...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2529640246?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-04-24 14:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2529640246","market":"us","top_or_hot":-1,"title":"港股异动 | 信达生物(01801)涨超5% IBI363（PD-1/IL-2α-bias）等多款管线将亮相2025 ASCO","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，信达生物(01801)涨超5%，截至发稿，涨5.05%，报54.05港元，成交额15.91亿港元。消息面上，4月24日，信达生物宣布将在美国临床肿瘤学会（ASCO）年会上展示肿瘤创新管线的一系列临床数据。其中，IBI363（PD-1/IL-2α-bias）在黑色素瘤、肠癌、非小细胞肺癌的临床研究，以及 IBI343（CLDN18.2 ADC）在胰腺癌研究方面均有口头报告。信迪利...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1283860.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 信达生物(01801)涨超5% IBI363（PD-1/IL-2α-bias）等多款管线将亮相2025 ASCO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 信达生物(01801)涨超5% IBI363（PD-1/IL-2α-bias）等多款管线将亮相2025 ASCO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-24 14:37 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1283860.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，信达生物(01801)涨超5%，截至发稿，涨5.05%，报54.05港元，成交额15.91亿港元。消息面上，4月24日，信达生物宣布将在美国临床肿瘤学会（ASCO）年会上展示肿瘤创新管线的一系列临床数据。其中，IBI363（PD-1/IL-2α-bias）在黑色素瘤、肠癌、非小细胞肺癌的临床研究，以及 IBI343（CLDN18.2 ADC）在胰腺癌研究方面均有口头报告。信迪利...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1283860.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2328871848.SGD","symbol_name":"Eastspring Investments - China A Shares Growth AS SGD","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1283860.html","article_id":"2529640246","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2529640246","pubTimestamp":1745476662,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，信达生物涨超5%，截至发稿，涨5.05%，报54.05港元，成交额15.91亿港元。消息面上，4月24日，信达生物宣布将在美国临床肿瘤学会年会上展示肿瘤创新管线的一系列临床数据。其中，IBI363在黑色素瘤、肠癌、非小细胞肺癌的临床研究，以及 IBI343在胰腺癌研究方面均有口头报告。本届 ASCO 年会将于当地时间2025年5月30日-6月3日在美国芝加哥举办。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","BK4023":"应用软件","BK1583":"高瓴概念","PD":"PagerDuty, Inc.","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","BK1589":"北水核心资产","01801":"信达生物","BK1161":"生物科技"},"translate_title":"Hong Kong stock changes Innovent Biologics (01801) rose more than 5% IBI363 (PD-1/IL-2α-bias) and other pipelines will be unveiled at ASCO 2025","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1,"PD":1},"content_text":"智通财经APP获悉，信达生物(01801)涨超5%，截至发稿，涨5.05%，报54.05港元，成交额15.91亿港元。消息面上，4月24日，信达生物宣布将在美国临床肿瘤学会（ASCO）年会上展示肿瘤创新管线的一系列临床数据。其中，IBI363（PD-1/IL-2α-bias）在黑色素瘤、肠癌、非小细胞肺癌的临床研究，以及 IBI343（CLDN18.2 ADC）在胰腺癌研究方面均有口头报告。信迪利单抗等药物在经典霍奇金淋巴瘤、局部晚期直肠癌、鼻咽癌等研究中也有成果展示。本届 ASCO 年会将于当地时间2025年5月30日-6月3日在美国芝加哥举办。交银国际此前指出，公司长期成长确定性强：在2024年实现non-IFRSEBITDA和净利润转正后，公司继续指引2027年收入200亿元、并提出到2030年将5个管线资产推入全球多中心III期临床的新目标。商业化和临床后期管线中，潜在重磅单品玛仕度肽、PD-1/IL-2、CLDN18.2 ADC是公司近期研发工作重心，未来12个月有多项数据读出值得期待，该行建议重点关注PD-1/IL-2在多种冷肿瘤上的PoC数据以及玛仕度肽多项糖尿病/减重III期数据。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"conferences,movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2529640246","isCrawlerRequest":true}